Self-assembled drug delivery systems. Part 8: In vitro/in vivo studies of the nanoassemblies of cholesteryl-phosphonyl gemcitabine

International Journal of Pharmaceutics

Volumn 478, Issue 1, 2015, Pages 124-130

  Li, Miao ^a   Qi, Shuo ^a,b   Jin, Yiguang ^a   Dong, Junxing ^a,b  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b BEIJING UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Gemcitabine; Molecular self assembly; Nanoassemblies; Phosphonate; Prodrug

Indexed keywords

AMPHOPHILE; CHOLESTEROL DERIVATIVE; GEMCITABINE; ANTINEOPLASTIC ANTIMETABOLITE; CHOLESTEROL; CHOLESTERYL-PHOSPHONYL GEMCITABINE; DEOXYCYTIDINE; NANOMATERIAL;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DISTRIBUTION HALF-LIFE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TISSUE LEVEL; ELIMINATION HALF-LIFE; HUMAN; HUMAN CELL; LYSOSOME; MACROPHAGE; MOUSE; NANOPHARMACEUTICS; NONHUMAN; TISSUE DISTRIBUTION; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL SURVIVAL; CHOLESTEROL; DEOXYCYTIDINE; DRUG DELIVERY SYSTEMS; HUMANS; MICE; NANOSTRUCTURES; NEOPLASMS; TUMOR BURDEN;

EID: 84911386981     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.11.033     Document Type: Article

References (31)

1. Beugin-Deroo, S., Ollivon, M., Lesieur, S., 1998. Bilayer stability and impermeability of nonionic surfactant vesicles sterically stabilized by PEG-cholesterol conjugates. J. Colloid Interface Sci. 202, 324-333.
2. Bradley, A.J., Devine, D.V., Ansell, S.M., Janzen, J., Brooks, D.E., 1998. Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol)-lipids. Arch. Biochem. Biophys. 357, 185-194.
3. Chen, D., Liu, W., Shen, Y., Mu, H., Zhang, Y., Liang, R., Wang, A., Sun, K., Fu, F., 2011. Effects of a novel pH-sensitive liposome with cleavable esterase-catalyzed and pH-responsive double smart mPEG lipid derivative on abc phenomenon. Int. J. Nanomed. 6, 2053-2061.
4. Du, L., Wu, L., Jin, Y., Jia, J., Li, M., Wang, Y., 2014. Self-assembled drug delivery systems. Part 7: hepatocyte-targeted nanoassemblies of an adefovir lipid derivative with cytochrome P450-triggered drug release. Int. J. Pharm. 472, 1-9.
5. Hong, M.-S., Lim, S.-J., Lee, M.-K., Kim, Y.B., Kim, C.-K., 2001. Prolonged blood circulation of methotrexate by modulation of liposomal composition. Drug Deliv. 8, 231-237.
6. Hung, S.W., Mody, H.R., Govindarajan, R., 2012. Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge. Cancer Lett. 320, 138-149.
7. Ishida, T., Ichihara, M., Wang, X., Yamamoto, K., Kimura, J., Majima, E., Kiwada, H., 2006. Injection of pegylated liposomes in rats elicits PEG-specific IGm, which is responsible for rapid elimination of a second dose of pegylated liposomes. J. Control. Release 112, 15-25.
8. Jin, Y., Tong, L., Ai, P., Li, M., Hou, X., 2006. Self-assembled drug delivery systems. 1. Properties and in vitro/in vivo behavior of acyclovir self-assembled nanoparticles (SAN). Int. J. Pharm. 309, 199-207.
9. Jin, Y., Xing, L., Tian, Y., Li, M., Gao, C., Du, L., Dong, J., Chen, H., 2009. Self-assembled drug delivery systems. Part 4. In vitro/in vivo studies of the self-assemblies of cholesteryl-phosphonyl zidovudine. Int. J. Pharm. 381, 40-48.
10. Jin, Y., Qi, N., Tong, L., Chen, D., 2010. Self-assembled drug delivery systems. Part 5: self-assemblies of a bolaamphiphilic prodrug containing dual zidovudine. Int. J. Pharm. 386, 268-274.
11. Jin, Y., Xin, R., Tong, L., Du, L., Li, M., 2011. Combination anti-HIV therapy with the self-assemblies of an asymmetric bolaamphiphilic zidovudine/didanosine prodrug. Mol. Pharm. 8, 867-876.
12. Jin, Y., Lian, Y., Du, L., 2012a. Self-assembly of N-acyl derivatives of gemcitabine at the air/water interface and the formation of nanoscale structures in water. Colloids Surf. A: Phys. Eng. Asp. 393, 60-65.
13. Jin, Y., Lian, Y., Du, L., Wang, S., Su, C., Gao, C., 2012b. Self-assembled drug delivery systems. Part 6: in vitro/in vivo studies of anticancer N-octadecanoyl gemcitabine nanoassemblies. Int. J. Pharm. 430, 276-281.
14. Jin, Y., Yang, F., Du, L., 2013. Nanoassemblies containing a fluorouracil/zidovudine glyceryl prodrug with phospholipase A2-triggered drug release for cancer treatment. Colloids Surf. B Biointerfaces 112, 421-428.
15. Korchowiec, B., Paluch, M., Corvis, Y., Rogalska, E., 2006. A langmuir film approach to elucidating interactions in lipid membranes: 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine/cholesterol/metal cation systems. Chem. Phys. Lipids 144, 127-136.
16. Kuang, Y., Liu, J., Liu, Z., Zhuo, R., 2012. Cholesterol-based anionic long-circulating cisplatin liposomes with reduced renal toxicity. Biomaterials 33, 1596-1606.
17. Mellman, I., 1996. Endocytosis and molecular sorting. Annu. Rev. Cell Dev. Biol. 12, 575-625.
18. Moghimi, S.M., Hunter, A.C., Murray, J.C., 2001. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53, 283-318.
19. Moghimi, S.M., Szebeni, J., 2003. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 42, 463-478.
20. Paolino, D., Cosco, D., Racanicchi, L., et al., 2010. Gemcitabine-loaded pegylated unilamellar liposomes vs gemzar®: biodistribution, pharmacokinetic features and in vivo antitumor activity. J. Control. Release 144, 144-150.
21. Papahadjopoulos, D., Allen, T.M., Gabizon, A., et al., 1991. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. U. S. A. 88, 11460-11464.
22. Pavey, K.D., Olliff, C.J., 1999. Spr analysis of the total reduction of protein adsorption to surfaces coated with mixtures of long- and short-chain polyethylene oxide block copolymers. Biomaterials 20, 885-890.
23. Sloat, B.R., Sandoval, M.A., Li, D., Chung, W.-G., Lansakara-P, D.S., Proteau, P.J., Kiguchi, K., DiGiovanni, J., Cui, Z., 2011. In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles. Int. J. Pharm. 409, 278-288.
24. Sroda, K., Rydlewski, J., Langner, M., Kozubek, A., Grzybek, M., Sikorski, A.F., 2005. Repeated injections of PEG-PE liposomes generate anti-PEG antibodies. Cell. Mol. Biol. Lett. 10, 37-47.
25. Suzuki, T., Ichihara, M., Hyodo, K., Yamamoto, E., Ishida, T., Kiwada, H., Ishihara, H., Kikuchi, H., 2012. Accelerated blood clearance of pegylated liposomes containing doxorubicin upon repeated administration to dogs. Int. J. Pharm. 436, 636-643.
26. Taurin, S., Nehoff, H., Greish, K., 2012. Anticancer nanomedicine and tumor vascular permeability; where is the missing link? J. Control. Release 164, 265-275.
27. Xiao, Q., Ju, Y., Yang, X., Zhao, Y.-F., 2003. Electrospray ionization mass spectrometry of AZT H-phosphonates conjugated with steroids. Rapid Commun. Mass 17, 1405-1410.
28. Xu, H., Deng, Y., Chen, D., Hong, W., Lu, Y., Dong, X., 2008. Esterase-catalyzed depegylation of pH-sensitive vesicles modi fied with cleavable peg-lipid derivatives. J. Control. Release 130, 238-245.
29. Yang, Q., Ma, Y., Zhao, Y., She, Z., Wang, L., Li, J., Wang, C., Deng, Y., 2013. Accelerated drug release and clearance of pegylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy. Int. J. Nanomed. 8, 1257-1268.
30. Zhang, Y., Kim, W.Y., Huang, L., 2013. Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLS and pancreatic cancer therapy. Biomaterials 34, 3447-3458.
31. Zhao, X.B., Muthusamy, N., Byrd, J.C., Lee, R.J., 2007. Cholesterol as a bilayer anchor for pegylation and targeting ligand in folate-receptor-targeted liposomes. J. Pharm. Sci. 96, 2424-2435.